Microvascular Complications-Neuropathy (D Ziegler, Section Editor)

Current Diabetes Reports

, Volume 13, Issue 4, pp 500-508

First online:

New and Developing Drugs for the Treatment of Neuropathic Pain in Diabetes

  • Roy FreemanAffiliated withCenter for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


A number of agents from diverse pharmacological classes are used to treat neuropathic pain associated with diabetic peripheral neuropathy. Only three of these have regulatory approval for this indication in the U.S. In this focused article, I will discuss selected drugs, newly approved or in development, to treat neuropathic pain in patients with diabetic neuropathy. These will include agonists and antagonists of the transient receptor potential channels, a family of receptor proteins that play a role in the transduction of physical stress; sodium channel isoform specific antagonists; a recently approved dual-action opioid receptor agonist–norepinephrine reuptake inhibitor; gene therapy for neuropathic pain; and anti-nerve growth factor molecules. Mechanisms of action, preclinical supporting data, clinical trial evidence, and adverse effects will be reviewed.


Neuropathic pain Diabetic peripheral neuropathy TRPV1 TRPA1capsaicin Sodium channel antagonists NaV1.7 Anti-NGF antibodies Gene therapy Tapentadol Diabetes